The Faculty of Medicine of The Chinese University of Hong Kong (CU Medicine) has entered into a strategic partnership with Chia Tai Tianqing Pharmaceutical Group Co. (CTTQ), a leading Chinese pharmaceutical company integral to Sino Biopharm.

This landmark Cooperation Framework Agreement aims to leverage the combined strengths of mainland China and Hong Kong in pharmaceutical innovation, research, talent development, and the commercialisation of medical products.

The collaboration will accelerate the translation of groundbreaking biomedical research into new diagnostic tests and treatments, providing patients quicker access to advanced healthcare solutions. Furthermore, it supports the development of Hong Kong as a pharmaceutical innovation hub in Asia and the Pacific.

The partnership will encompass various collaborative endeavours, including:

1. Clinical Trials: Implementation of Phase I to Phase III clinical trials in Hong Kong and across Asia
2. Commercialisation: Exploration of opportunities for commercialising CUHK-developed drugs and medical devices through licensing or startup investments
3. Research Funding: Joint establishment of funding schemes to support innovative research projects
4. Talent Development: Collaborative efforts to enhance learning and exchange between CU Medicine students and CTTQ researchers
5. Academic Conferences: Organisation of annual academic conferences to foster knowledge sharing